查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2019247

心血管醫療設備市場：商機、成長要素、產業趨勢分析及2026-2035年預測

Cardiovascular Devices Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035
出版日期: | 出版商: Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2025 年，全球心血管器材市場價值將達到 740 億美元，並預計以 7.5% 的複合年成長率成長，到 2035 年達到 1,520 億美元。

心血管器材市場-IMG1

心血管疾病盛行率上升、全球人口老化、政府醫療保健政策加強以及對微創治療需求不斷成長，是推動心血管醫療器材市場擴張的主要因素。心血管醫療設備包括植入式、體外和診斷系統，用於監測、輔助或恢復心臟和血管功能。它們有助於檢測異常情況、改善血液循環、調節心率、增強血流並支持長期疾病管理。器械技術的進步、小型化、創新材料和數位化整合提高了臨床準確性、安全性和易用性。先進支架、電生理解決方案和成像工具等創新技術能夠實現更早期的檢測和更有效的治療，從而推動了醫生對這些技術的採用。微創手術，包括經導管心臟瓣膜置換術術和機器人輔助手術系統，減輕了手術負擔、縮短了住院時間並降低了治療成本，促使醫院和心臟中心優先採用最先進的精準導向器械。

市場範圍
開始年份 2025
預測期 2026-2035
上市時的市場規模 740億美元
預測金額 1520億美元
複合年成長率 7.5%

預計到2025年，治療和外科醫療設備市場規模將達到604億美元。這個市場涵蓋了重要的心血管器械，例如導管、冠狀動脈介入治療器械、心臟節律管理系統、結構性心臟疾病器械和手術器械。這些器械在恢復或替代心臟功能方面發揮著至關重要的作用，是介入性心臟病學和心臟外科的核心。該市場透過提供治療緊急或危及生命的心臟疾病所需的根治性療法來推動市場成長。持續的產品創新，包括微創導管、新一代支架、更先進的心律不整管理器械和耐用型人工心臟瓣膜，正在改善治療效果、縮短住院時間並擴大其在高風險患者中的應用範圍。

預計到2025年，心律不整市場規模將達255億美元。專為心律不整治療而設計的設備佔據了市場的大部分佔有率，這主要得益於心房顫動、心搏過速和心搏過緩等心律不整盛行率的不斷上升。與生活方式相關的風險因素，例如老化、肥胖、高血壓和糖尿病，以及對持續監測需求的日益成長，都在推動市場的持續成長。心律不整檢測和治療技術的進步，包括先進的監測系統和植入式設備，正在鞏固該領域的市場地位，並支持其長期成長。

到2025年，北美循環系統器材市場將佔據全球41.8%的佔有率。該地區因久坐不動的生活方式、肥胖和高血壓而導致的高疾病負擔，推動了對先進診斷和治療解決方案的強勁需求。醫院和專科醫療中心正擴大採用微創心臟器械，例如支架、心律調節器、去心房顫動和監測系統，以治療日益增多的患者。心血管疾病（CVD）相關住院人數的增加，加速了創新介入器材的應用，而心臟器材的持續改善也與該地區的醫療保健需求和監管標準相契合。

目錄

第1章：調查方法

  • 研究途徑
  • 品質改進計劃
    • GMI人工智慧政策和資料完整性計劃
      • 資訊來源一致性協議
  • 調查過程和可靠性評分
    • 調查過程的組成部分
    • 評分組成部分
  • 數據收集
    • 主要來源部分列表
  • 資料探勘資訊來源
    • 付費資訊來源
      • 區域資訊來源
  • 基本估算和計算方法
    • 每種方法中基準年的計算
  • 預測模型
    • 量化市場影響分析
      • 生長參數對預測的數學影響
  • 關於調查透明度的補充信息
    • 資訊來源歸屬框架
    • 品質保證指標
    • 對信任的承諾

第2章執行摘要

第3章業界考察

  • 生態系分析
  • 影響產業的因素
    • 促進因素
      • 患有心血管疾病的患者人數正在增加。
      • 老年人口增加
      • 政府主導的措施增加
      • 心血管器械的技術進步
      • 對微創手術的需求日益成長
    • 產業潛在風險與挑戰
      • 心血管手術風險較高
      • 嚴格的法規環境
    • 市場機遇
      • 人工智慧在心血管疾病領域的應用日益廣泛
  • 成長潛力分析
  • 監理情勢（基於初步調查）
  • 技術趨勢（基於初步調查）
    • 當前技術趨勢
      • 用於即時心血管診斷的先進成像和感測系統
      • 用於自動檢測和風險分層的AI整合式心血管設備
    • 新興技術
      • 用於下一代心血管植入和支架的生物工程和自適應材料
      • 用於動態心血管評估的超高速 3D 視覺化數位雙胞胎技術
  • 未來市場趨勢（基於初步研究）
  • 2025年價格分析
  • 人工智慧和生成式人工智慧對市場的影響
  • 波特五力分析
  • PESTEL 分析

第4章 競爭情勢

  • 介紹
  • 企業市佔率分析
    • 世界
    • 北美洲
    • 歐洲
    • 亞太地區
  • 企業矩陣分析
  • 主要市場公司的競爭分析
  • 競爭定位矩陣
  • 主要進展
    • 併購
    • 夥伴關係與合作
    • 新產品發布
    • 業務拓展計劃

第5章 市場估計與預測：依類型分類，2022-2035年

  • 診斷和監測設備
    • 心電圖系統
    • 動態心電圖和心臟事件記錄器
    • 遠端心電圖監測設備
    • 心臟診斷超音波設備
    • 其他診斷和監測設備
  • 治療及外科器械
    • 導管
      • 電生理消融導管
      • 電生理診斷及標測導管
      • 介入導管
    • 冠狀動脈介入裝置
      • 藥物釋放型支架
      • 裸金屬支架
      • 生物可吸收支架
      • PTCA球囊
      • 動脈粥狀硬化斑塊切除術裝置
      • 導管導引線
      • 栓塞預防裝置
      • 其他冠狀動脈介入裝置
    • 心臟節律管理（CRM）設備
      • 心律調節器
      • 植入式心臟整流去顫器
      • 心臟再同步治療裝置
      • 植物型循環記錄器
      • 其他心臟節律管理裝置
    • 結構性心臟裝置
      • 左心耳封堵裝置
      • 心臟瓣膜
    • 心臟外科手術器械
      • 冠狀動脈繞道手術手術（CABG）手術器械
      • 其他心臟外科器械
    • 心室輔助裝置

第6章 市場估計與預測：依應用領域分類，2022-2035年

  • 冠狀動脈疾病
  • 心律不整
  • 心臟衰竭
  • 其他用途

第7章 市場估計與預測：依最終用途分類，2022-2035年

  • 醫院
  • 門診手術中心
  • 心臟中心
  • 其他最終用戶

第8章 市場估計與預測：依地區分類，2022-2035年

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第9章：公司簡介

  • Abbott Laboratories
  • AngioDynamics
  • Biotronik
  • Boston Scientific
  • Johnson &Johnson MedTech
  • Koninklijke Philips
  • Medtronic
  • Meril Life Sciences
  • MicroPort Scientific
  • Olympus
  • Penumbra
  • Relisys Medical Devices
  • Sahajanand Medical Technologies
  • Terumo
  • Translumina Therapeutics
簡介目錄
Product Code: 4949

The Global Cardiovascular Devices Market was valued at USD 74 billion in 2025 and is estimated to grow at a CAGR of 7.5% to reach USD 152 billion by 2035.

Cardiovascular Devices Market - IMG1

The expansion is fueled by the rising prevalence of cardiovascular diseases, an aging global population, increased government healthcare initiatives, and growing demand for minimally invasive interventions. Cardiovascular devices include implantable, external, and diagnostic systems that monitor, support, or restore heart and vascular function. They help detect irregularities, improve circulation, regulate heart rhythms, enhance blood flow, and assist in long-term disease management. Advancements in device technology, miniaturization, innovative materials, and digital integration have improved clinical precision, safety, and usability. Innovations like advanced stents, electrophysiology solutions, and imaging tools enable earlier detection and more effective treatment, encouraging physician adoption. Minimally invasive procedures, including transcatheter heart valves and robotic-assisted systems, reduce surgical trauma, shorten hospital stays, and lower treatment costs, prompting hospitals and cardiology centers to prioritize cutting-edge, precision-guided devices.

Market Scope
Start Year2025
Forecast Year2026-2035
Start Value$74 Billion
Forecast Value$152 Billion
CAGR7.5%

The therapeutic and surgical devices segment reached USD 60.4 billion in 2025. This segment encompasses essential cardiovascular tools such as catheters, coronary intervention devices, cardiac rhythm management systems, structural heart devices, and surgical instruments. These devices play a critical role in restoring or replacing heart function and are central to interventional cardiology and cardiac surgery. The segment dominates due to its provision of definitive treatments, often necessary for urgent or life-threatening cardiac conditions. Continuous product innovations, including minimally invasive catheters, next-generation stents, smarter rhythm management devices, and durable heart valves, enhance procedural outcomes, reduce hospital stays, and expand eligibility for high-risk patients.

The cardiac arrhythmia segment generated USD 25.5 billion in 2025. Arrhythmia-focused devices hold a major share because of the increasing prevalence of irregular heart rhythms such as atrial fibrillation, tachycardia, and bradycardia. Aging populations, lifestyle-related risk factors like obesity, hypertension, and diabetes, and the rising need for continuous monitoring drive sustained demand. Technological progress in arrhythmia detection and therapy, including advanced monitoring systems and implantable devices, strengthens the segment's market position and supports long-term growth.

North America Cardiovascular Devices Market accounted for 41.8% share in 2025. The region's high disease burden, driven by sedentary lifestyles, obesity, and hypertension, fuels strong demand for advanced diagnostic and therapeutic solutions. Hospitals and specialty centers increasingly adopt minimally invasive cardiac devices, such as stents, pacemakers, defibrillators, and monitoring systems, to treat a growing patient population. Rising CVD-related hospitalizations accelerate the adoption of innovative interventional devices, while continuous improvements in cardiology equipment align with the region's healthcare needs and regulatory standards.

Key players in the Global Cardiovascular Devices Market include Abbott Laboratories, Boston Scientific, Biotronik, Johnson & Johnson MedTech, Terumo, AngioDynamics, Olympus, Medtronic, Meril Life Sciences, Penumbra, Sahajanand Medical Technologies, Koninklijke Philips, Translumina Therapeutics, Relisys Medical Devices, and MicroPort Scientific. Companies in the Global Cardiovascular Devices Market strengthen their position by prioritizing innovation and expanding their product portfolios to include advanced, minimally invasive, and digitally integrated devices. Firms invest heavily in R&D to develop next-generation stents, rhythm management systems, structural heart devices, and robotic-assisted technologies. Strategic partnerships with hospitals and research institutions accelerate clinical adoption and market penetration. Global expansion into emerging markets and targeted collaborations with distributors ensure wider geographic reach. Companies also focus on regulatory compliance, quality assurance, and physician training programs to build trust and drive adoption.

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Research approach
  • 1.2 Quality commitments
    • 1.2.1 GMI AI policy & data integrity commitment
      • 1.2.1.1 Source consistency protocol
  • 1.3 Research trail & confidence scoring
    • 1.3.1 Research trail components
    • 1.3.2 Scoring components
  • 1.4 Data collection
    • 1.4.1 Partial list of primary sources
  • 1.5 Data mining sources
    • 1.5.1 Paid sources
      • 1.5.1.1 Sources, by region
  • 1.6 Base estimates and calculations
    • 1.6.1 Base year calculation for any one approach
  • 1.7 Forecast model
    • 1.7.1 Quantified market impact analysis
      • 1.7.1.1 Mathematical impact of growth parameters on forecast
  • 1.8 Research transparency addendum
    • 1.8.1 Source attribution framework
    • 1.8.2 Quality assurance metrics
    • 1.8.3 Our commitment to trust

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Device type trends
    • 2.2.2 Application trends
    • 2.2.3 End use trends
    • 2.2.4 Regional trends
  • 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing number of patients suffering from cardiovascular diseases
      • 3.2.1.2 Expanding geriatric population
      • 3.2.1.3 Rising government initiatives
      • 3.2.1.4 Technological advancements in cardiovascular devices
      • 3.2.1.5 Rising demand for minimally invasive procedures
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High risk associated with cardiac procedures
      • 3.2.2.2 Stringent regulatory scenario
    • 3.2.3 Market opportunities
      • 3.2.3.1 Increasing applications of AI in cardiovascular diseases
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape (Driven by primary research)
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
    • 3.4.4 Latin America
    • 3.4.5 Middle East and Africa
  • 3.5 Technology landscape (Driven by primary research)
    • 3.5.1 Current technological trends
      • 3.5.1.1 Advanced imaging and sensing systems for real-time cardiovascular diagnostics
      • 3.5.1.2 AI-integrated cardiovascular devices for automated detection and risk stratification
    • 3.5.2 Emerging technologies
      • 3.5.2.1 Bioengineered and adaptive materials for next-generation cardiovascular implants and stents
      • 3.5.2.2 Ultra-high-speed 3D visualization and digital twin technologies for dynamic cardiovascular assessment
  • 3.6 Future market trends (Driven by primary research)
  • 3.7 Pricing analysis, 2025
  • 3.8 Impact of AI and Generative AI on the market
  • 3.9 Porter's analysis
  • 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 Global
    • 4.2.2 North America
    • 4.2.3 Europe
    • 4.2.4 Asia Pacific
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Mergers and acquisitions
    • 4.6.2 Partnerships and collaborations
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Type, 2022 - 2035 ($ Mn)

  • 5.1 Key trends
  • 5.2 Diagnostic and monitoring devices
    • 5.2.1 Electrocardiogram systems
    • 5.2.2 Holter and event monitors
    • 5.2.3 Remote cardiac monitoring devices
    • 5.2.4 Cardiac diagnostic ultrasound
    • 5.2.5 Other diagnostic and monitoring devices
  • 5.3 Therapeutic and surgical devices
    • 5.3.1 Catheters
      • 5.3.1.1 Electrophysiology ablation catheters
      • 5.3.1.2 Electrophysiology diagnostic and mapping catheters
      • 5.3.1.3 Interventional catheters
    • 5.3.2 Coronary intervention devices
      • 5.3.2.1 Drug eluting stents
      • 5.3.2.2 Bare metal stents
      • 5.3.2.3 Bioresorbable scaffolds
      • 5.3.2.4 PTCA balloons
      • 5.3.2.5 Atherectomy devices
      • 5.3.2.6 Guidewires
      • 5.3.2.7 Embolic protection devices
      • 5.3.2.8 Other coronary intervention devices
    • 5.3.3 Cardiac rhythm management (CRM) devices
      • 5.3.3.1 Pacemakers
      • 5.3.3.2 Implantable cardioverter defibrillators
      • 5.3.3.3 Cardiac resynchronization therapy devices
      • 5.3.3.4 Implantable loop recorders
      • 5.3.3.5 Other cardiac rhythm management devices
    • 5.3.4 Structural heart devices
      • 5.3.4.1 LAA closure devices
      • 5.3.4.2 Heart valves
    • 5.3.5 Cardiac surgery devices
      • 5.3.5.1 Coronary artery bypass graft (CABG) surgical tools
      • 5.3.5.2 Other cardiac surgical devices
    • 5.3.6 Ventricular assist devices

Chapter 6 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

  • 6.1 Key trends
  • 6.2 Coronary artery disease
  • 6.3 Cardiac arrhythmia
  • 6.4 Heart failure
  • 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Ambulatory surgical centers
  • 7.4 Cardiac centers
  • 7.5 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 Abbott Laboratories
  • 9.2 AngioDynamics
  • 9.3 Biotronik
  • 9.4 Boston Scientific
  • 9.5 Johnson & Johnson MedTech
  • 9.6 Koninklijke Philips
  • 9.7 Medtronic
  • 9.8 Meril Life Sciences
  • 9.9 MicroPort Scientific
  • 9.10 Olympus
  • 9.11 Penumbra
  • 9.12 Relisys Medical Devices
  • 9.13 Sahajanand Medical Technologies
  • 9.14 Terumo
  • 9.15 Translumina Therapeutics